Supernus Pharmaceuticals (SUPN)
(Delayed Data from NSDQ)
$30.26 USD
+0.31 (1.04%)
Updated Apr 24, 2024 04:00 PM ET
5-Strong Sell of 5 5
D Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for Supernus Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 608 | 667 | 580 | 520 | 393 |
Cost Of Goods | 84 | 87 | 75 | 52 | 17 |
Gross Profit | 524 | 580 | 505 | 468 | 376 |
Selling & Adminstrative & Depr. & Amort Expenses | 529 | 534 | 419 | 294 | 228 |
Income After Depreciation & Amortization | -5 | 46 | 86 | 174 | 149 |
Non-Operating Income | 10 | 22 | 11 | 19 | 22 |
Interest Expense | 2 | 7 | 23 | 24 | 23 |
Pretax Income | 3 | 61 | 73 | 169 | 147 |
Income Taxes | 1 | 0 | 20 | 42 | 34 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 1 | 61 | 53 | 127 | 113 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 1 | 61 | 53 | 127 | 113 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 80 | 137 | 137 | 206 | 167 |
Depreciation & Amortization (Cash Flow) | 85 | 91 | 51 | 32 | 18 |
Income After Depreciation & Amortization | -5 | 46 | 86 | 174 | 149 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 55.51 | 61.68 | 54.36 | 53.69 | 53.82 |
Diluted EPS Before Non-Recurring Items | 0.02 | 1.04 | 0.98 | 2.36 | 2.10 |
Diluted Net EPS (GAAP) | 0.02 | 1.04 | 0.98 | 2.36 | 2.10 |
Fiscal Year end for Supernus Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 164.31 | 153.88 | 135.56 | 153.76 |
Cost Of Goods | NA | 19.63 | 19.60 | 21.09 | 23.46 |
Gross Profit | NA | 144.69 | 134.28 | 114.47 | 130.30 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 145.69 | 126.14 | 132.06 | 125.13 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -1.00 | 8.14 | -17.59 | 5.17 |
Non-Operating Income | NA | 1.99 | 1.75 | 1.37 | 5.35 |
Interest Expense | NA | 0.00 | 0.00 | 0.91 | 1.51 |
Pretax Income | NA | 0.99 | 9.89 | -17.13 | 9.02 |
Income Taxes | NA | -0.19 | 25.87 | -16.30 | -7.93 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 1.18 | -15.98 | -0.83 | 16.95 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 1.17 | -15.98 | -0.83 | 16.95 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 55.30 | 54.61 | 54.50 | 62.45 |
Diluted EPS Before Non-Recurring Items | NA | 0.02 | -0.29 | -0.02 | 0.29 |
Diluted Net EPS (GAAP) | NA | 0.04 | -0.29 | -0.02 | 0.29 |